Accessibility Menu
 
Phibro Animal Health logo

Phibro Animal Health

(NASDAQ) PAHC

Current Price$50.83
Market Cap$2.06B
Since IPO (2014)+276%
5 Year+128%
1 Year+136%
1 Month-0%

Phibro Animal Health Financials at a Glance

Market Cap

$2.06B

Revenue (TTM)

$1.46B

Net Income (TTM)

$92.09M

EPS (TTM)

$2.26

P/E Ratio

22.50

Dividend

$0.48

Beta (Volatility)

0.89 (Low)

Price

$50.83

Volume

10,717

Open

$52.37

Previous Close

$50.83

Daily Range

$50.13 - $52.37

52-Week Range

$16.16 - $56.30

PAHC: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Phibro Animal Health

Industry

Pharmaceuticals

Employees

2,475

CEO

Jack C. Bendheim

Headquarters

Teaneck, NJ 07666-6712, US

PAHC Financials

Key Financial Metrics (TTM)

Gross Margin

32%

Operating Margin

12%

Net Income Margin

6%

Return on Equity

32%

Return on Capital

15%

Return on Assets

7%

Earnings Yield

4.44%

Dividend Yield

0.01%

Payout Ratio

21.13%

Stock Overview

Market Cap

$2.06B

Shares Outstanding

40.58M

Volume

10.72K

Short Interest

0.00%

Avg. Volume

262.83K

Financials (TTM)

Gross Profit

$399.94M

Operating Income

$110.47M

EBITDA

$146.85M

Operating Cash Flow

$80.12M

Capital Expenditure

$38.29M

Free Cash Flow

$41.83M

Cash & ST Invst.

$77.04M

Total Debt

$761.55M

Phibro Animal Health Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$373.91M

+20.9%

Gross Profit

$132.66M

+30.2%

Gross Margin

35.48%

N/A

Market Cap

$2.06B

N/A

Market Cap/Employee

$1.06M

N/A

Employees

1,940

N/A

Net Income

$27.46M

+762.1%

EBITDA

$67.31M

+163.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Net Cash

$698.66M

+3.3%

Accounts Receivable

$215.87M

+12.6%

Inventory

$517.35M

+21.1%

Long Term Debt

$743.57M

-2.8%

Short Term Debt

$29.60M

+22.0%

Return on Assets

6.55%

N/A

Return on Invested Capital

15.09%

N/A

Free Cash Flow

$8.26M

+273.9%

Operating Cash Flow

$19.35M

+529.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AVDLAvadel Pharmaceuticals plc
$21.64+0.00%
AUPHAurinia Pharmaceuticals Inc.
$14.02-0.36%
MDPediatrix Medical Group, Inc.
$19.70-0.96%
ANIPANI Pharmaceuticals, Inc.
$74.67-0.20%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
RITMRithm Capital
$8.77-0.03%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.82+0.06%
INFYInfosys
$13.12+0.01%

Questions About PAHC

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.